Treatment Options
249 articles
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
Rewinding 2025: A Year in Pancreatic Cancer Research
We take a look back at the research developments in 2025: KRAS, earlier detection and screening, vaccines, and clinical trials.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Chemotherapy Plus Immunotherapy Trial Shows Promise
Dr. Gulam Manji leads a clinical trial that uses two types of immunotherapy to enhance chemotherapy for pancreatic cancer patients.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Cancer Commons and xCures Hope to Use Real-World Data to Improve Care
Lola Rahib and Patrick van der Valk explain how Cancer Commons and xCures are using real-world data to improve care for future patients.
Researching More Second-Line Options for Pancreatic Cancer
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metastatic pancreatic cancer.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
Making Surgery An Option for More Pancreatic Cancer Patients
Dr. John Chabot explains that more pancreatic cancer patients may qualify for surgery if they consult an experience pancreatic surgical team.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
Tumor Biology Matters
Dr. Lynn Matrisian of PanCAN, explains that molecular profiling of a pancreatic cancer patient’s tumor can show which treatment will work best.
DIRECT Study Focuses on NanoKnife Technology
Dr. Daniel Holzwanger is part of the NanoKnife irreversible electroporation (IRE) study for stage III pancreatic cancer patients.
Ablative SMART Radiotherapy Could Be Beneficial for Advanced Pancreatic Cancer
Learn the advantages of radiation treatment for pancreatic cancer with an MRI-guided system as researched by radiation oncologist Dr. Michael Chuong.